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Abstract
Several recently reported evidence-based phase 3 trials that focus on the role of cytotoxic
chemotherapy have the potential to strongly influence the care of women with advanced epithelial
ovarian cancer. Particular areas of interest include: (a) neoadjuvant chemotherapy; (b) chemotherapy
of recurrent platinum-sensitive ovarian cancer; and (c) the relevance of paclitaxel scheduling in the
primary chemotherapeutic management of the malignancy. This report will briefly discuss the results
of these studies and the potential implications of the findings for routine care of patients in these
clinical settings.
Introduction and context
An attempt at optimal surgical cytoreduction prior to the
initiation of cytotoxic chemotherapy has long been
recognized as the standard-of-care management strategy
in women presenting with advanced epithelial ovarian
cancer [1,2]. However, multiple reports over the course
of more than a decade have suggested that in carefully
selected patients the administration of chemotherapy
prior to an attempt at surgery (neoadjuvant chemother-
apy) is an acceptable or perhaps even a superior option
(reduced treatment-related morbidity) [3,4].
Standard treatment of advanced ovarian cancer includes a
platinum agent plus a taxane [1], with most oncologists
employing a regimen of carboplatin plus either paclitaxel
or docetaxel. Of note, the taxane in these programs has
beenroutinelyadministeredonan every-3-week schedule.
Several previously published phase 3 randomized trials
have revealed the superiority of combination plati-
num-based chemotherapy in recurrent ovarian cancer
(platinum-free interval >6 months) compared with
single-agent platinum [5,6]. However, it remained
unknown whether there would be any difference in
outcome depending on which known biologically
active drug in ovarian cancer is added to platinum
(generally carboplatin) in a two-drug combination
strategy (e.g., docetaxel, gemcitabine, paclitaxel, pegy-
lated liposomal doxorubicin [PLD], and topotecan).
Recent advances
In what is likely to be considered a landmark study in the
gynecologic cancer arena, a multinational cooperative
group effort directly compared (phase 3 randomized
trial) primary surgery followed by chemotherapy (‘con-
trol arm’) with an experimental neoadjuvant approach
(chemotherapy followed by interval surgical cytoreduc-
tion) in women with large-volume intra-abdominal
epithelial ovarian cancer [7]. The study revealed no
difference in overall survival between the two study
arms, with less serious therapy-associated morbidity
(and mortality) for women randomly assigned to the
neoadjuvant approach.
The trial has received criticism due to the overall poor
survival of the study population and questions of the
adequacy of surgery (low rate of optimal debulking)
across the multiple participant institutions and
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excellent design (phase 3 randomized trial) and conduct,
stratification by country (an important response to the
issue of the adequacy of surgery), and the observation
that there was no suggestion of a survival benefit
associated with the primary surgical approach.
The results of the recently reported CALYPSO (Caelyx
[pegylated liposomal doxorubicin hydrochloride] in
Platinum-Sensitive Ovarian Patients) trial have provided
provocative evidence supporting the superiority of the
combination of carboplatin plus PLD compared with
carboplatin plus paclitaxel in this clinical setting [8]. The
study, designed as a non-inferiority phase 3 randomized
trial, demonstrated a statistically significant improve-
ment in median progression-free survival (11.3 versus
9.4 months; P = 0.005; hazard ratio [HR] 0.821) in favor
of the PLD-containing regimen. Data regarding overall
survival were not mature at the time of the initial
presentation of the efficacy results. Perhaps even more
provocative than the interesting survival data was the
observation that patients treated with the carboplatin/
PLD program experienced an impressively lower risk for
the development of carboplatin-associated hypersensi-
tivity reactions and a corresponding reduced risk of
having treatment on the protocol discontinued due to
excessive toxicity [9].
As solid (although certainly not definitive) data support
the conclusion that the platinum agents are the single
mostbiologicallyactivedrugsinovariancancer(including
intheplatinum-sensitivesecond-linesetting),itispossible
that the observed superiority of the carboplatin/PLD
regimen (compared with carboplatin/paclitaxel) resulted,
at least in part, from the ability of a larger percentage of
patients with potentially platinum-sensitive tumors to
receive an optimal number of cycles of carboplatin.
While this concept must be considered only hypothesis-
generating, the available data certainly support the
conclusion. Furthermore, a previously reported small
phase 3 randomized trial conducted by the Southwest
Oncology Group that compared single-agent carboplatin
with the combination of carboplatin plus PLD revealed a
similar striking reduction in the incidence of carboplatin-
associated hypersensitivity reactions in the two-drug
regimen [10,11].
An acceptable biological explanation for this observation
remains to be established. However, it is conceivable that
the pegylated liposomal preparation itself may have
some impact on the development of clinically relevant
hypersensitivity. This important observation requires
further investigation as the negative impact associated
with the sudden onset of serious carboplatin allergic
reactions is well known [9].
Arecentlyreportedrandomizedphase3trialconductedby
the Japanese Gynecologic Oncology Group revealed the
superiority of carboplatin plus weekly paclitaxel com-
bined with every-3-week carboplatin compared with the
same dose and schedule of the platinum agent but with
paclitaxel administered on the ‘standard’ every-3-week
program [12]. The weekly paclitaxel strategy was asso-
ciated with improved progression-free survival (median
28 versus 17.2 months; P = 0.0015; HR 0.71) and 3-year
overall survival (72.1% versus 65.1%; P = 0.03; HR 0.75).
Implications for clinical practice
The data obtained in the landmark phase 3 neoadjuvant
chemotherapy trial support the conclusion that, in
carefully selected patients with advanced ovarian cancer
(e.g., extensive disease requiring bowel resection to
achieve an optimal residual state or the presence of co-
morbidity increasing the risks associated with aggressive
cytoreductive surgery), primary chemotherapy followed
by an attempt at surgical cytoreduction (when appro-
priate) is an acceptable management strategy. Future
research in this area, including exploration of a possible
role for intraperitoneal chemotherapy following success-
ful interval surgical cytoreduction, is clearly indicated. Of
note, a phase 3 multinational cooperative group trial
examining this specific issue has recently been activated.
The results of the CALPYSO trial reveal that the
combination of carboplatin plus PLD is an acceptable
treatment strategy in potentially platinum-sensitive
recurrent ovarian cancer.
While it will be important for the potentially paradigm-
changing data in the Japanese front-line weekly pacli-
taxel trial to be confirmed in a second phase 3 study,
highly relevant support for the superiority of weekly
paclitaxel comes from two recently reported randomized
breast cancer trials (metastatic disease and adjuvant
treatment) that revealed the superiority of weekly
paclitaxel administration compared with the ‘standard’
every-3-week regimen [13,14]. Considered together, the
available data strongly support the conclusion that
carboplatin plus weekly paclitaxel is an acceptable and
likely superior regimen for the chemotherapeutic man-
agement of advanced ovarian cancer.
Abbreviations
HR, hazard ratio; PLD, pegylated liposomal doxorubicin.
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